Skip to main content
Premium Trial:

Request an Annual Quote

Japan's Yamatake Licenses OGT's Oligo IP to Develop Microarrays

NEW YORK (GenomeWeb News) – Japan’s Yamatake has licensed Oxford Gene Technology’s oligonucleotide microarray patents to make and sell its own arrays, OGT said today.
 
Yamatake will manufacture gemkey microarrays using in situ synthesis. Yamatake is the only Japanese company using in situ synthesis, said Michael Bennett, OGT’s vice president of licensing.
 
The company will market the microarrays through its distributor, Sigma-Aldrich Japan.
 
The license will remain valid for the patents’ lifetime.
 
Yamatake is the second Japanese company this month to license the patents from OGT: Japan’s NGK Insulators signed a similar deal Aug. 1.
 
Financial details were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.